- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07419880
Réadministration de l'immunothérapie avec Cromolyn, TQB2102 et Panpulimab dans le cancer du sein triple négatif réfractaire à l'immunothérapie (RECLAIM)
RECLAIM : Rechallenge de l'immunothérapie avec le Cromolyn, le TQB2102 et le Panpulimab dans le cancer du sein triple négatif réfractaire à l'immunothérapie
RECLAIM: A Phase II, Open-Label, Single-Arm, Multicenter Clinical Trial of Cromolyn, TQB2102, and Panpulimab for Re-Challenging Immune-Refractory Triple-Negative Breast Cancer
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a phase II, open-Label, single-arm, multicenter clinical trial investigating the efficacy and safety of cromolyn for potentiating ADC combined with immunotherapy in refractory triple-negative breast cancer. Based on previous findings, the infiltration level of antigen-presenting mast cells (apMCs) was significantly correlated with clinical benefits from immunotherapy. Cromolyn, a mast cell membrane stabilizer, demonstrated promising efficacy in the phase II "Renaissance" clinical study. Among 10 patients with anti-PD-1/PD-L1-resistant TNBC, the combination of cromolyn with chemotherapy and immunotherapy achieved an objective response rate (ORR) of 50%. To further validate these findings, we have designed this study to enroll TNBC patients who have progressed after conventional treatments (including chemotherapy, immunotherapy, ADC, etc.), with the aim of further investigating the synergistic effects of cromolyn sodium combined with ADC and PD-1 monoclonal antibody against refractory TNBC tumors at the clinical level.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Zhimin Shao
- Numéro de téléphone: +88807 08664175590
- E-mail: zhimingshao@yahoo.com
Sauvegarde des contacts de l'étude
- Nom: Zhonghua Wang
- Numéro de téléphone: +88807 08664175590
- E-mail: zhonghuawang95@hotmail.com
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200032
- Fudan University Shanghai Cancer Center
-
Contact:
- Zhimin Shao
- Numéro de téléphone: +88807 08664175590
- E-mail: zhimingshao@yahoo.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Age: Female, ≥18 years old and ≤70 years old.
-
Diagnosis: Histologically confirmed invasive triple-negative breast cancer (defined as: ER-negative by IHC with <1% positive tumor cells; PR-negative with <1% positive tumor cells; HER2 0-1+ or HER2 2+ with confirmed negative FISH/CISH without amplification).
-
Prior Treatment: Recurrent or metastatic refractory breast cancer with disease progression after prior immunotherapy.
-
Measurable Disease: At least one measurable lesion per RECIST v1.1 (≥20 mm by conventional CT or ≥10 mm by spiral CT; lesion must not have been previously irradiated).
-
Organ Function: Adequate organ function as follows:
- Blood Counts: Hemoglobin ≥90 g/L (no transfusion within 14 days); absolute neutrophil count ≥1.5×10⁹/L; platelets ≥75×10⁹/L.
- Blood Chemistry: Total bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN (≤5×ULN if liver metastases are present); serum creatinine ≤1×ULN; creatinine clearance >50 mL/min (Cockcroft-Gault formula).
-
Treatment-Free Interval: No radiotherapy, endocrine therapy, molecular targeted therapy, or major surgery within 3 weeks prior to study entry; recovery from prior treatment-related toxicities (surgical wounds fully healed if applicable); absence of peripheral neuropathy or only grade I peripheral neuropathy.
-
Performance Status: ECOG performance status ≤1, and life expectancy ≥3 months.
-
Contraception: Women of childbearing potential must agree to use medically approved contraception during the study treatment period and for at least 3 months after the last dose of the study drug.
-
Consent: Voluntary participation with signed informed consent, good compliance, and willingness to cooperate with follow-up.
Exclusion Criteria:
- Prior Radiotherapy: Receipt of radiotherapy within 3 weeks before treatment initiation (except for palliative reasons).
- CNS Metastases: Known history or presence of central nervous system (CNS) metastases at screening. Patients with clinical suspicion of CNS metastases must undergo contrast-enhanced CT or MRI within 28 days prior to the first dose to rule out CNS involvement.
- Cardiac Disease: History of clinically significant or uncontrolled cardiac conditions, including congestive heart failure, angina, myocardial infarction within the past 6 months, or ventricular arrhythmia.
- Persistent Toxicity: Ongoing ≥ Grade 1 adverse reactions from previous treatments, except for alopecia or conditions deemed acceptable by the investigator. Such exceptions must be clearly documented in the investigator's notes.
- Recent Major Surgery: Undergone major surgery (excluding minor outpatient procedures such as vascular access placement) within 3 weeks before the first cycle of study treatment.
- Pregnancy or Lactation: Patients who are pregnant or breastfeeding.
- Other Malignancies: History of other malignant tumors within the past 5 years (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).
- Impaired Drug Absorption: Conditions affecting oral drug intake and absorption, such as dysphagia, chronic diarrhea, or intestinal obstruction.
- Uncontrolled Effusions: Uncontrolled third-space effusions (e.g., significant pleural or ascitic fluid) not manageable by drainage or other methods.
- Non-Healing Conditions: Long-term non-healing wounds or incompletely healed fractures.
- Active Viral Hepatitis: Active HBV or HCV infection (HBV-DNA ≥ 500 IU/mL) or chronic hepatitis with abnormal liver function.
- Allergic History: Known allergy or hypersensitivity to any component of the study regimen, or history of hypersensitivity to other monoclonal antibodies.
- Eosinophilia/Mastocytosis: Patients with eosinophilia or mastocytosis.
- Steroid Use: Chronic use of oral corticosteroids. Occasional past use requires a 4-week washout period before enrollment.
- Prior Use of Specific Therapies: Previous treatment with PD-1/TGF-β bispecific antibody, PD-1/CTLA-4 bispecific antibody, PD-1/VEGF bispecific antibody, or anti-HER2 dual-epitope ADC; or use of ADC agents in ≥2 prior lines of therapy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cromolyn plus TQB2102and Panpulimab
Cromolyn:a mast cell membrane stabilizer;TQB2102: HER2-ADC; Panpulimab: anti PD-1 |
Upon enrollment, patients will receive intravenous administration of penpulimab (200 mg) and TQB2102 (6 mg/kg) every three weeks, along with intranasal delivery of cromolyn sodium (each dose 10 mg [5 sprays per nostril, bilaterally], four times daily, administered 30 minutes before meals and at bedtime). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate (ORR)
Délai: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1) |
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease Control Rate(DCR)
Délai: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Complete remission or partial remission or stable disease (according to RECIST1.1) |
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
|
Progression Free Survival(PFS)
Délai: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Time to progressive disease (according to RECIST1.1) |
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
|
Overall Survival (OS)
Délai: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Time to death due to any cause |
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Translational alalyses
Délai: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
HER2, PD-L1, and mast cell status will be measured in pre-treatment tissues. Plasma inflammatory molecules and peripheral immune cells will be measured in pre- and on-treatment blood. |
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Zhimin Shao, Fudan University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies de la peau
- Maladies du sein
- Tumeurs mammaires
- Maladies de la peau et du tissu conjonctif
- Tumeurs mammaires triples négatives
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Pyrans
- Benzopyrans
- Chromones
- Cromolyne sodique
Autres numéros d'identification d'étude
- SCHBCC-N0106
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .